1921
The Global Pandemic of Falsified Medicines: Laboratory and Field Innovations and Policy Implications
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
Preview this article:
Zoom in
Zoomout

The Global Pandemic of Falsified Medicines: Laboratory and Field Innovations and Policy Perspectives, Page 1 of 1

| /docserver/preview/fulltext/14761645/92/6_Suppl/2-1.gif

There is no abstract available for this article.
Use the preview function to the left.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.15-0221
2015-06-03
2020-07-09
Loading full text...

Full text loading...

/deliver/fulltext/14761645/92/6_Suppl/2.html?itemId=/content/journals/10.4269/ajtmh.15-0221&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2014. World Malaria Report 2014. Available at: http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/. Accessed March 15, 2015.
    [Google Scholar]
  2. World Health Organization, 2014. Global Tuberculosis Report 2014. Available at: http://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf. Accessed March 14, 2015.
    [Google Scholar]
  3. Joint United Nations Programme on HIV/AIDS, 2014. 2014 Progress Report on the Global Plan towards the Elimination of New HIV Infections among Children by 2015 and Keeping Their Mothers Alive. Available at: http://www.unaidsrstesa.org/sites/default/files/jc2681_2014-global-plan-progress_en.pdf. Accessed March 15, 2015.
    [Google Scholar]
  4. Hamburg M, 2015. Foreword to the global pandemic of falsified medicines: laboratory and field innovations and policy implications. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 1.[Crossref]
    [Google Scholar]
  5. Tabernero P, Fernandez FM, Green M, Guerin P, Newton PN, 2014. Mind the Gaps—the Epidemiology of Poor-Quality Anti-Malarials in the Malarious World—Analysis of the Worldwide Antimalarial Resistance Network Database. Mal J 13: 139. Available at: http://www.malariajournal.com/content/13/1/139. Accessed March 15, 2015.[Crossref]
    [Google Scholar]
  6. O'Conner A, 2015. New York Attorney General targets supplements at major retailers. New York Times. Available at: http://well.blogs.nytimes.com/2015/02/03/new-york-attorney-general-targets-supplements-at-major-retailers/. Accessed March 15, 2015.
    [Google Scholar]
  7. World Health Organization, 2015. Essential Medicines—General information on Counterfeit Medicines. Available at: http://www.who.int/medicines/services/counterfeit/overview/en/. Accessed March 15, 2015.
    [Google Scholar]
  8. Blackstone EA, Fuhr JP Jr, Pociask S, 2014. The health and economic effects of counterfeit drugs. Am Health Drug Benefits 7: 216224.
    [Google Scholar]
  9. Nayyar GML, Breman JG, Newton PN, Herrington J, 2012. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 12: 488496.[Crossref]
    [Google Scholar]
  10. World Health Organization, 2010. Preliminary Draft Survey on National Legislation on “Counterfeit Medicines”: Feedback from Member States to the Circular Letter CL 25.2009. Available at: http://www.who.int/medicines/services/counterfeit/WHO_ACM_Report.pdf. Accessed March 15, 2015.
    [Google Scholar]
  11. Amin AA, Bird C, Passmore P, Dukes G, Tomson G, Simons B, Bate R, Philippe GJ, White NJ, Newton PN, 2011. The primacy of public health considerations in defining poor quality medicines. PLoS Med 8: e1001139. Available at: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001139. Accessed March 15, 2015.[Crossref]
    [Google Scholar]
  12. Renschler JP, Walters K, Newton P, Laxminarayan P, 2015. Estimating under-five deaths associated with poor quality antimalarials in sub-Saharan Africa. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 119126.[Crossref]
    [Google Scholar]
  13. Institute of Medicine, 2013. Countering the Problem of Falsified and Substandard Drugs. Washington, DC: The National Academies Press. Available at: https://www.iom.edu/Reports/2013/Countering-the-Problem-of-Falsified-and-Substandard-Drugs.aspx. Accessed March 15, 2015.
    [Google Scholar]
  14. Kovacs S, Hawes SE, Maley SN, Mosites E, Wong L, Stergachis A, 2014. Technologies for detecting falsified and substandard drugs in low and middle-income countries. PLoS One 9: e90601. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0090601. Accessed March 15, 2015.
    [Google Scholar]
  15. Weaver AA, Lieberman M, 2015. Paper-based test cards for field detection of falsified and very low quality (VLQ) anti-infective and anti-malarial medications. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 1723.[Crossref]
    [Google Scholar]
  16. Green MD, Hostetler DM, Nettey H, Ranieri N, Swamidoss I, Fernandez F, Newton P, Cinnamond M, 2015. Integration of novel low-cost colorometric and visual fluorescent techniques for rapid identification of counterfeit artemether-lumefantrine and other drugs in resource poor areas. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 816.[Crossref]
    [Google Scholar]
  17. Ho NT, Desai D, Zaman MH, 2015. Rapid, sensitive and specific drug quality testing assay for antimalarials using luminescent reaction and novel microfluidic technology. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 2430.[Crossref]
    [Google Scholar]
  18. Kaur H, Seifert K, Hawkes G, Coumbarides G, Alvar J, Croft SL, 2015. Chemical and bioassay techniques to authenticate quality of the antileishmanial drug miltefosine. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 3138.[Crossref]
    [Google Scholar]
  19. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, the WHO Leishmaniasis Control Team, 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035671. Accessed March 15, 2015.[Crossref]
    [Google Scholar]
  20. World Health Organization, 2014. Report of the Third Meeting of the Member State Mechanism on Substandard/Spurious/Falsely Labelled Falsified/Counterfeit Medical Products. Available at: http://apps.who.int/gb/ssffc/pdf_files/MSM3/A_MSM3_3-en.pdf. Accessed March 15, 2015.
    [Google Scholar]
  21. United States Pharmacopeial Convention, 2015. Medicines Quality Database (MQDB). Available at: http://www.usp.org/global-health-programs/promoting-quality-medicines-pqmusaid/medicines-quality-database-mqdb. Accessed March 15, 2015.
    [Google Scholar]
  22. Yeung S, Lawford HLS, Tabernero P, Nguon C, van Wyk A, Malik N, DeSousa M, Rada O, Boravann M, Dwivedi P, Hostetler DM, Swamidoss I, Green MD, Fernandez FM, Kaur H, 2015. Quality of antimalarials at the epicenter of antimalarial drug resistance: results from an overt and mystery client survey in Cambodia. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 3950.[Crossref]
    [Google Scholar]
  23. Lalani M, Kaur H, Mohammed N, Amanzai O, Mailk N, van Wyk A, Rashid H, Jan S, Kakar RM, Mojadidi MK, Leslie T, 2015. Substandard antimalarials available in Afghanistan: a case for assessing the quality of drugs in resource poor settings. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 5158.[Crossref]
    [Google Scholar]
  24. ACT Consortium Drug Quality Project Team and the IMPACT2 Study Team, 2015. Quality of artemisinin containing antimalarials in Tanzania's private sector—results from a nationally representative outlet survey. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 7586.
    [Google Scholar]
  25. Hajjou M, Krech L, Lane-Barrow C, Roth L, Pribluda V, Phanouvong S, El Hadri L, Evans L, Raymond C, Yuan E, Lang S, Voung T-A, Okafor R, Chibew K, Lukulay P, 2015. Monitoring the quality of medicines: results from Africa, southeast Asia, and Latin America. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 6874.[Crossref]
    [Google Scholar]
  26. Tabernero P, Mayxay M, Culzoni MJ, Dwivedi P, Swamidoss I, Allan EL, Khanthavong M, Phonlavong C, Vilayhong C, Yeuchaixiong S, Sichanh C, Sengaloundeth S, Kaur H, Fernandez FM, Green MD, Newton P, 2015. A repeat random survey of the prevalence of falsified and substandard antimalarials in the Lao PDR—a change for the better. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 95104.[Crossref]
    [Google Scholar]
  27. Fadeyi I, Lalani M, Mailk N, van Wyk A, Kaur H, 2015. Quality of the antibiotics—amoxicillin and cotrimoxazole from Ghana, Nigeria, and the United Kingdom. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 8794.[Crossref]
    [Google Scholar]
  28. Yong YL, Plançon A, Lau YH, Hostetler D, Fernandez F, Green M, Sounvoravong S, Nara S, Boravann M, Dumrong T, Bangsawan N, Tuc VV, Low MY, Lim CC, Lee R, Ai C, Newton P, 2015. Collaborative health and enforcement operations on the quality of antimalarials and antibiotics in SE Asia. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 105112.[Crossref]
    [Google Scholar]
  29. Worldwide Antimalarial Resistance Network, 2015. Antimalarial Quality Surveyor. Available at: http://www.wwarn.org/resistance/surveyors/antimalarial-quality. Accessed March 15, 2015.
    [Google Scholar]
  30. Kaiser Health News, 2009. WHO Launches Counterfeit Drug Reporting System in Western Pacific Region. Available at: http://kaiserhealthnews.org/morning-breakout/dr00029898/. Accessed March 15, 2015.
    [Google Scholar]
  31. Mackey TM, Liang BA, York P, Kubic T, 2105. Empirical analysis of counterfeit drug penetration in global legitimate supply chains: a descriptive assessment. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 5967.
    [Google Scholar]
  32. Nayyar GML, Attaran A, Clark JP, Culzoni M, Fernandez F, Herrington JE, Kendall M, Newton P, Breman JG, 2015. Responding to the pandemic of falsified medicines. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 113118.[Crossref]
    [Google Scholar]
  33. Attaran A, 2015. Stopping murder by medicine: introducing the model law against medicine crime. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 127132.[Crossref]
    [Google Scholar]
  34. Callard C, 2010. Follow the money: how the billions of dollars that flow from smokers in poor nations to companies in rich nations greatly exceed funding for global tobacco control and what might be done about it. Tob Control 19: 285. Available at: http://tobaccocontrol.bmj.com/content/19/4/285/T1.expansion.html. Accessed March 15, 2015.[Crossref]
    [Google Scholar]
  35. Cinnamond M, Woods T, 2015. The Joint Inter-Agency Task Force and the Global Steering Committee for the Quality Assurance of Health Products: two new and proactive approaches to promoting access to safe and effective medicines. Herrington JE, Nayyar GML, Breman JG, eds. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg 92 (Suppl 6): 133136.[Crossref]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0221
Loading
/content/journals/10.4269/ajtmh.15-0221
Loading

Data & Media loading...

  • Received : 20 Mar 2015
  • Accepted : 10 Apr 2015
  • Published online : 03 Jun 2015
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error